News

Every September, Blood Cancer Awareness Month shines a spotlight on the more than 20,000 Australians and New Zealanders  diagnosed with blood cancer such as leukaemia, lymphoma and myeloma each year. Sadly, nearly 6,000 people will die from their disease. Blood Cancer Awareness Month is a time to raise awareness, recognise the experiences of patients and families, and highlight the important role research plays in improving outcomes.

The Australasian Leukaemia and Lymphoma Group (ALLG) is committed to delivering clinical trials to people living with blood cancer. This Blood Cancer Month, support us, and help us highlight why research matters. Together we can help drive the next breakthrough.

Fundraise For Us

Go Red4Research

Behind every clinical trial are patients, researchers, healthcare teams and supporters working together to create change. This Blood Cancer Awareness Month, you can turn research into hope by funding research that leads to improved outcomes and provides more options for people living with blood cancer.

Whether you, Go Red4Research, make a donation, host a fundraising event or simply share the message, you will help accelerate the discoveries that can change lives.

Hope for People with Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL) is one of the most common types of adult blood cancer. While many people can live with CLL for years, the disease can by unpredictable. Some people may not need treatment for a long time, while others may experience their cancer returning or becoming harder to treat.

This is why clinical research is so important. ALLG researchers are working with Australian, New Zealand and International partners to explore new treatment approaches that could help people with CLL achieve longer-lasting responses and a better quality of life.

New CLL clinical trials are helping researchers answer important questions about the future of treatment.

• CLL10 CLL RT-2  aims to focus on patients with Richter Transformation, a rare and aggressive complication of CLL where the disease changes into a faster-growing blood cancer and targets a high-unmet need
• The CLL11 MOONSHOT trial explores whether adding a newer treatment approach after initial therapy can help higher-risk CLL achieve a deeper and longer-lasting response to treatment
• CLL12 AETHER trial will investigate new treatment combinations for people whose CLL has returned or become more difficult to treat, with the aim of finding better options for patients who need further therapies

Every clinical trial brings new knowledge, new possibilities and new hope for people affected by blood cancer.

A Future Shaped by Research

Every advance in blood cancer treatment starts with research. Thanks to the commitment of patients, clinicians, researchers and supporters, clinical trials continue to drive progress and open the door to new possibilities for people living with blood cancer. While there is still more work to be done, each study brings us closer to more effective treatments, improved quality of life and better outcomes for patients and their families. This Blood Cancer Awareness Month, we recognise the impact of research and the hope it creates for future generations.